The excipients market thrives on innovation, driving advancements that revolutionize pharmaceutical formulations. These additives, ranging from binders to coatings, play a pivotal role in drug delivery systems. With a surge in novel drug formulations, the Excipients market witnesses unprecedented growth, offering multifaceted benefits. Manufacturers leverage cutting-edge technologies to enhance drug stability, bioavailability, and solubility, amplifying therapeutic outcomes. Moreover, excipients ensure precise dosage administration, fostering patient compliance and safety. This dynamic landscape fosters collaborations and investments, fueling research endeavors for novel excipients. Consequently, the excipients market emerges as a cornerstone of pharmaceutical development, spearheading advancements that redefine therapeutic possibilities while ensuring efficacy and patient well-being.
Data Bridge Market Research analyses that the Global Excipients Market size is projected to reach USD 7,757.00 million in 2022, is expected to reach USD 12,633.93 million by 2030, and is expected to undergo a CAGR of 6.00% during the forecast period 2023-2030.
Below are the Top Five Excipients Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
DOW
|
Dow is a leading supplier of excipients, offering a diverse portfolio of products catering to various industries, including pharmaceuticals. With a focus on innovation, Dow delivers high-quality excipients that enhance the performance and functionality of pharmaceutical formulations. Their excipient offerings encompass a wide range of functionalities, ensuring compatibility and stability in drug formulations. Leveraging its expertise in material science, Dow continuously develops novel excipients to meet the evolving needs of the pharmaceutical industry, maintaining a strong presence in the excipients market globally.
|
|
North America, South America, Europe, Asia-Pacific
|
In December 2018, the four U.S. sites of Dow company received EXCiPACT certificate from SGS, which will help them to supply pharmaceutical excipients in the U.S. This has also increased the revenue of the company.
|
|
2.
|
Roquette Frères
|
Roquette Frères is a prominent supplier in the excipients market, renowned for its cutting-edge solutions and commitment to quality. Specializing in natural-based excipients, Roquette offers a comprehensive portfolio that includes starches, sugars, and polyols, catering to diverse pharmaceutical formulations. With a strong emphasis on research and development, the company continually innovates to address industry challenges and optimize drug delivery performance. Roquette's excipients are known for their functionality, biocompatibility, and sustainability, meeting the stringent requirements of pharmaceutical manufacturers globally. By fostering partnerships and leveraging its global presence, Roquette Frères remains a trusted provider of high-performance excipients in the pharmaceutical industry.
|
|
North America, South America, Europe, Asia-Pacific
|
In September 2020, the company entered into a partnership with Barentz for pharmaceutical distribution in the U.S. both these companies are working in European markets, creating distribution channel. This partnership will increase the product portfolio of the company.
|
|
3.
|
JRS PHARMA
|
JRS PHARMA is a key player in the excipients market and is renowned for its expertise in functional excipients and pharmaceutical ingredients. With a focus on innovation and quality, JRS PHARMA offers a diverse portfolio of excipients, including cellulose derivatives, binders, and disintegrants, designed to enhance drug formulation and performance. The company's excipients are characterized by their superior functionality, compatibility, and regulatory compliance, catering to a wide range of pharmaceutical applications. Leveraging state-of-the-art manufacturing facilities and a strong commitment to research and development, JRS PHARMA continues to deliver innovative solutions that meet the evolving needs of the pharmaceutical industry worldwide.
|
|
Middle East and Africa, Europe, America, and Asia-Pacific
|
In November 2020, Stryker announced the acquisition of Wright Medical Group N.V., a global medical device company focused on extremities and biologics. Wright Medical is a recognized leader in the upper extremities, lower extremities, and biologics market segments. It also has advanced preoperative planning technology, which can further help in Stryker’s growth. Thus, the acquisition enhanced the company’s global market position in trauma and extremities.
|
|
4.
|
Evonik Industries AG
|
Evonik Industries AG is a leading supplier of specialty excipients and functional additives for the pharmaceutical industry. With a focus on performance and sustainability, Evonik offers a diverse portfolio of excipients, including solubilizers, polymers, and coatings, designed to improve drug stability, bioavailability, and patient compliance. Leveraging advanced technologies and expertise in material science, the company delivers tailor-made solutions that meet the unique formulation challenges of pharmaceutical manufacturers. Evonik's excipients are known for their reliability, quality, and regulatory compliance, making them the preferred choices for drug formulation worldwide. By fostering collaboration and innovation, Evonik remains at the forefront of driving advancements in pharmaceutical excipients.
|
|
North America, South America, Europe, Asia-Pacific, Africa, Oceania
|
In January 2021, Evonik completed the acquisition of LACTEL an absorbable polymer from DURECT Corporation. This will help the company to expand its business and make its product profile strong.
|
|
5.
|
The Lubrizol Corporation
|
The Lubrizol Corporation is a global leader in specialty chemicals, offering a wide range of excipients and functional additives for the pharmaceutical industry. With a focus on performance and sustainability, Lubrizol provides innovative excipients that enhance drug solubility, stability, and delivery. The company's portfolio includes polymers, surfactants, and rheology modifiers, catering to diverse pharmaceutical formulations and dosage forms. Leveraging its extensive expertise and state-of-the-art manufacturing capabilities, Lubrizol delivers high-quality excipients that meet the stringent requirements of pharmaceutical manufacturers worldwide. By prioritizing customer collaboration and technological innovation, Lubrizol remains a trusted partner for enhancing pharmaceutical formulations and driving product development in the industry.
|
|
North America, South America, Europe, Asia-Pacific
|
In July 2019, the Lubrizol Corporation renamed its personal healthcare domain to Lubrizol life science. This will help the company attract more customers and strengthen its product profile.
|
Conclusion
In conclusion, the excipients market is poised for significant growth, driven by the rising demand for pharmaceutical formulations and novel drug delivery systems. Opportunities abound for excipient manufacturers to innovate and cater to evolving consumer needs, particularly in emerging markets. With increasing investments in research and development, alongside advancements in technology, the excipients industry is primed to play a pivotal role in shaping the future of pharmaceuticals, ensuring safer and more effective treatments for global populations.
